FDA Must Maintain Oversight Role In PMI Development, Groups Urge
This article was originally published in The Pink Sheet Daily
Executive Summary
Advocates argue patient medication information documents could resemble advertising if FDA does not review and approve them before they are used, regardless of resources concerns.
You may also be interested in...
FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?
FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.
FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?
FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.
Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets
Manufacturers would have full responsibility for writing, producing, and ultimately delivering the new patient medication information document with their products, if FDA decides the industry should fully adopt the unit-of-use packaging.